Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VYGR Voyager Therapeutics

Market Closed 01-16 16:00:00 EST

3.76

-0.06

-1.57%

盘后3.78

+0.02+0.53%

17:54 EST

High3.95	Low3.72	Vol569.27K
Open3.83	D1 Closing3.82	Amplitude5.89%
Mkt Cap209.06M	Tradable Cap172.29M	Total Shares55.60M
T/O2.19M	T/O Rate1.24%	Tradable Shares45.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VYGR","market":"US","secType":"STK","nameCN":"Voyager Therapeutics","latestPrice":3.76,"timestamp":1768597200000,"preClose":3.82,"halted":0,"volume":569272,"hourTrading":{"tag":"盘后","latestPrice":3.78,"preClose":3.76,"latestTime":"17:54 EST","volume":3426,"amount":12919.0331,"timestamp":1768604070517,"change":0.02,"changeRate":0.005319,"amplitude":0},"delay":0,"changeRate":-0.015706806282722526,"floatShares":45820683,"shares":55600084,"eps":-2.169056,"marketStatus":"Market Closed","change":-0.06,"latestTime":"01-16 16:00:00 EST","open":3.83,"high":3.945,"low":3.72,"amount":2185006.83082,"amplitude":0.058901,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.169056,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1447218000000,"exchange":"NASDAQ","adjPreClose":3.82,"preHourTrading":{"tag":"盘前","latestPrice":3.85,"preClose":3.82,"latestTime":"09:29 EST","volume":3254,"amount":12568.31045,"timestamp":1768573799227,"change":0.03,"changeRate":0.007853,"amplitude":0.028796},"postHourTrading":{"tag":"盘后","latestPrice":3.78,"preClose":3.76,"latestTime":"17:54 EST","volume":3426,"amount":12919.0331,"timestamp":1768604070517,"change":0.02,"changeRate":0.005319,"amplitude":0},"volumeRatio":0.6357322924415942,"impliedVol":10.4683,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/VYGR","defaultTab":"news","newsList":[{"id":"2602316207","title":"Voyager Therapeutics Files Initial Beneficial Ownership Statement for Gregory L. Shiferman, SVP and General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2602316207","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602316207?lang=en_us&edition=fundamental","pubTime":"2026-01-09 07:08","pubTimestamp":1767913724,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Gregory L. Shiferman, who serves as Senior Vice President and General Counsel, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL7w9qMN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Voyager Therapeutics Files Initial Beneficial Ownership Statement for Gregory L. Shiferman, SVP and General Counsel","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2583304326","title":"Voyager Therapeutics Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2583304326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583304326?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:55","pubTimestamp":1762973700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VYGR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 13:55 ET (18:55 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR"],"gpt_icon":0},{"id":"2583303159","title":"Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Skye Bioscience (SKYE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583303159","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583303159?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:50","pubTimestamp":1762962610,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report) and Skye Bioscience...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-voyager-therapeutics-vygr-and-skye-bioscience-skye-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4585","BK4581","VYGR","XLV","BK4137","LU0128526141.USD","XBI","LU0029874061.USD","HCSG","LABU","SKYE"],"gpt_icon":0},{"id":"2583303179","title":"Voyager Therapeutics price target lowered to $25 from $30 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2583303179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583303179?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:40","pubTimestamp":1762962031,"startTime":"0","endTime":"0","summary":"H.C. Wainwright lowered the firm’s price target on Voyager Therapeutics (VYGR) to $25 from $30 and keeps a Buy rating on the shares. Voyager report...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-price-target-lowered-to-25-from-30-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-price-target-lowered-to-25-from-30-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2582430803","title":"Voyager Therapeutics Inc : H.c. Wainwright Cuts Target Price to $25 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2582430803","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582430803?lang=en_us&edition=fundamental","pubTime":"2025-11-12 23:38","pubTimestamp":1762961935,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nFWN3WO16G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582537648","title":"Voyager Therapeutics (VYGR) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2582537648","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582537648?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:36","pubTimestamp":1762950981,"startTime":"0","endTime":"0","summary":"In a report released today, from Wells Fargo maintained a Buy rating on Voyager Therapeutics, with a price target of $10.00. Voyager Therapeutics h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-receives-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/voyager-therapeutics-vygr-receives-a-buy-from-wells-fargo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1201861249.SGD","BK4585","LU0128525689.USD","LU0267386448.USD","LU0971096721.USD","LU0942090050.USD","LU0052756011.USD","IE00B7SZLL34.SGD","LU0787776722.HKD","LU0640476718.USD","LU1506573853.SGD","LU0175139822.USD","LU0417517546.SGD","LU2361044949.HKD","LU0742534661.SGD","LU0211327993.USD","LU2236285917.USD","BK4588","BK4559","LU1363072403.SGD","LU1074936037.SGD","LU1035773651.USD","LU0154236417.USD","LU0106831901.USD","LU0251131958.USD","LU0310800379.SGD","LU0683600562.USD","LU1069347547.HKD","BK4504","BK4207","LU0251142724.SGD","IE0002270589.USD","LU1280957306.USD","IE00B19Z3581.USD","LU1267930227.SGD","LU0149725797.USD","VYGR","LU0256863811.USD","LU0208291251.USD","LU0310799852.SGD","LU1814569148.SGD","LU0708994859.HKD","LU1267930573.SGD","LU0314106906.USD","LU1267930490.SGD","LU0868494708.USD","LU0320765489.SGD","LU2461242641.AUD","LU1668664300.SGD","LU2361044865.SGD"],"gpt_icon":0},{"id":"2582619753","title":"Analysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582619753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582619753?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:11","pubTimestamp":1762866703,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alpha Teknova (TKNO – Research Report), Voyager Therapeutics (VYG...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alpha-teknova-tkno-voyager-therapeutics-vygr-and-terns-pharmaceuticals-tern-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alpha-teknova-tkno-voyager-therapeutics-vygr-and-terns-pharmaceuticals-tern-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4581","BK4007","BK4588","BK4137","XLV","TKNO","LABU","VYGR","BK4139","TERN","BK4539","BK4585","BK4121","XBI","LU0128526141.USD","LU0029874061.USD"],"gpt_icon":0},{"id":"2582366678","title":"Wedbush Keeps Their Buy Rating on Voyager Therapeutics (VYGR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366678","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366678?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:19","pubTimestamp":1762863589,"startTime":"0","endTime":"0","summary":"In a report released today, Yun Zhong from Wedbush reiterated a Buy rating on Voyager Therapeutics, with a price target of $8.00. According to TipR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-voyager-therapeutics-vygr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-keeps-their-buy-rating-on-voyager-therapeutics-vygr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2582388504","title":"Voyager Therapeutics files $400M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2582388504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582388504?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:10","pubTimestamp":1762809018,"startTime":"0","endTime":"0","summary":"16:09 EST Voyager Therapeutics (VYGR) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-files-400m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-files-400m-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582807253","title":"Voyager Therapeutics Inc Files for Mixed Shelf Offering of up to $400 Mln- SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807253","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807253?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:03","pubTimestamp":1762808635,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nFWN3WM2BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582011758","title":"Voyager Therapeutics price target lowered to $11 from $12 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2582011758","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582011758?lang=en_us&edition=fundamental","pubTime":"2025-11-11 02:25","pubTimestamp":1762799124,"startTime":"0","endTime":"0","summary":"Leerink lowered the firm’s price target on Voyager Therapeutics (VYGR) to $11 from $12 and keeps an Outperform rating on the shares. Voyager Therap...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-price-target-lowered-to-11-from-12-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-price-target-lowered-to-11-from-12-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0},{"id":"2582711398","title":"Voyager Therapeutics, Transition Bio entered into drug discovery collab","url":"https://stock-news.laohu8.com/highlight/detail?id=2582711398","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582711398?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:10","pubTimestamp":1762780209,"startTime":"0","endTime":"0","summary":"Transition Bio and Voyager Therapeutics (VYGR) have entered into a drug discovery collaboration and license option agreement. The companies will co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-transition-bio-entered-into-drug-discovery-collab-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/voyager-therapeutics-transition-bio-entered-into-drug-discovery-collab-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2582718558","title":"Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2582718558","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582718558?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:09","pubTimestamp":1762780142,"startTime":"0","endTime":"0","summary":"Biotech firm Voyager's Q3 collaboration revenue drops, net loss widensOverviewVoyager Q3 collaboration revenue falls due to lower Novartis agreement revenueNet loss widens in Q3 2025 due to increased ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0HW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU0823416689.USD","LU2065171402.SGD","VYGR","BK4139","LU2324357040.USD","LU2065171311.SGD","LU0154245756.USD","LU2065170008.USD","NBIX","LU0154245673.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2582879084","title":"Voyager Therapeutics and Transition Bio Partner to Develop Small Molecule Therapies for ALS and FTD","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879084","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879084?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:07","pubTimestamp":1762780077,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. has announced a collaboration with Transition Bio to discover and develop novel small molecule therapies targeting TDP-43 for the treatment of amyotrophic lateral sclerosis  and frontotemporal dementia . Under the agreement, Transition Bio will focus on the discovery and optimization of small molecules up to the nomination of a development candidate, after which Voyager has the option to license exclusive global rights for further development and commercialization. Transition Bio will receive an upfront payment in the single-digit millions and is eligible for milestone payments totaling up to $500 million, as well as high single-digit to low double-digit royalties on net sales. The partnership leverages Transition Bio's molecular condensate technology and Voyager's expertise in neurotherapeutics to address the challenges of targeting TDP-43 pathology in neurodegenerative diseases.Disclaimer: This news brief was created by Public Technologies  using generative ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbJRjYM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582879265","title":"Voyager Therapeutics reports third quarter revenue of $13.4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879265","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879265?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:04","pubTimestamp":1762779867,"startTime":"0","endTime":"0","summary":"Voyager Therapeutics Inc. reported collaboration revenue of $13.4 million for the third quarter of 2025, down from $24.6 million in the same period of 2024, primarily due to lower revenue recognized under the 2022 Novartis Option and License Agreement. As of September 30, 2025, the company held cash, cash equivalents, and marketable securities totaling $229 million and expects this to fund operations into 2028. During the period, Novartis discontinued two discovery-stage programs, with rights to these targets returning to Voyager; however, partnered programs for Huntington's disease, spinal muscular atrophy, and another undisclosed target continue to advance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. publ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7dywtM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582879411","title":"BRIEF-Voyager Therapeutics Q3 Collaboration Revenue USD 13.365 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879411","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879411?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:01","pubTimestamp":1762779705,"startTime":"0","endTime":"0","summary":"BRIEF-Voyager Therapeutics Q3 Collaboration Revenue USD 13.365 Million\n\n\nNov 10 (Reuters) - Voyager Therapeutics Q3 operating income USD -30.594 million.\n\nQ3 pretax profit USD -27.809 million\nQ3 net income USD -27.892 million\nQ3 basic EPS USD -0.47","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX3FC784:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2582101879","title":"Voyager Therapeutics Q3 Operating Income USD -30.594 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582101879","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582101879?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:01","pubTimestamp":1762779660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX3FC784:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582879486","title":"Voyager Therapeutics Inc - Transition Bio Eligible for up to $500M in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879486?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:01","pubTimestamp":1762779660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA7SPWYF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VYGR","BK4139"],"gpt_icon":0},{"id":"2582879176","title":"Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting Tdp-43 in ALS and Frontotemporal Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879176","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879176?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:01","pubTimestamp":1762779660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA7SPWYF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VYGR"],"gpt_icon":0},{"id":"2574127234","title":"Voyager Therapeutics: Strategic Positioning and Regulatory Endorsements Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2574127234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574127234?lang=en_us&edition=fundamental","pubTime":"2025-10-10 18:35","pubTimestamp":1760092531,"startTime":"0","endTime":"0","summary":"Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Voyager Therapeutics, retaining the price target of $30.00. Patrick Trucchio...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strategic-positioning-and-regulatory-endorsements-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/voyager-therapeutics-strategic-positioning-and-regulatory-endorsements-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VYGR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.voyagertherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0647},{"period":"1month","weight":-0.1174},{"period":"3month","weight":-0.2404},{"period":"6month","weight":0.1605},{"period":"1year","weight":-0.2569},{"period":"ytd","weight":-0.0433}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.001043},{"month":2,"riseRate":0.5,"avgChangeRate":0.058533},{"month":3,"riseRate":0.5,"avgChangeRate":0.047541},{"month":4,"riseRate":0.5,"avgChangeRate":0.019214},{"month":5,"riseRate":0.6,"avgChangeRate":0.041264},{"month":6,"riseRate":0.5,"avgChangeRate":0.010419},{"month":7,"riseRate":0.4,"avgChangeRate":-0.019026},{"month":8,"riseRate":0.6,"avgChangeRate":-0.020662},{"month":9,"riseRate":0.2,"avgChangeRate":0.071458},{"month":10,"riseRate":0.3,"avgChangeRate":-0.010359},{"month":11,"riseRate":0.4,"avgChangeRate":-0.07862},{"month":12,"riseRate":0.454545,"avgChangeRate":-0.036226}],"exchange":"NASDAQ","name":"Voyager Therapeutics","nameEN":"Voyager Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Voyager Therapeutics,VYGR,Voyager Therapeutics股票,Voyager Therapeutics股票老虎,Voyager Therapeutics股票老虎国际,Voyager Therapeutics行情,Voyager Therapeutics股票行情,Voyager Therapeutics股价,Voyager Therapeutics股市,Voyager Therapeutics股票价格,Voyager Therapeutics股票交易,Voyager Therapeutics股票购买,Voyager Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Voyager Therapeutics(VYGR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Voyager Therapeutics(VYGR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}